A Rapid Clinical Digital Patient-derived Organoid to Guide Breast Cancer Treatment Decision
Grant Award Details
Grant Type:
Grant Number:
TRAN2-16061
Investigator(s):
Award Value:
$1,535,375
Status:
Pre-Active
Grant Application Details
Application Title:
A Rapid Clinical Digital Patient-derived Organoid to Guide Breast Cancer Treatment Decision
Public Abstract:
Translational Candidate
The digital patient organoid (DPO) assay is a microfluidic miniature organoid technology that allows high-throughput drug testing.
Area of Impact
Our functional DPO assay will guide personalized therapy in patients with MBC and fulfill a gap of huge unmet need
Mechanism of Action
DPO is a microfluidic miniature organoid technology that enables breast cancer stem cells to form organoids rapidly in the presence of original tumor stromal and immune cells in droplet-sized (250 uM) balls made of extracellular matrix, which is a high-throughput, high-fidelity patient-derived model for rapid drug testing and maintains the original tumor microenvironment and enable personalized treatment for patients with metastatic cancers.
Unmet Medical Need
Metastatic breast cancer (MBC) remains incurable despite recent incorporation of antibody drug conjugates (ADCs). With the fast-paced clinical development of multiple ADCs in the MBC space, lack of trial data or clinical algorithm guiding subsequent therapy following initial ADC resistance, such as a different ADC or combination. There is urgent need for development of novel precision medicine tool using a reliable and rapid turn-round assay guiding treatment selection in these patients.
Project Objective
Pre-IND
Major Proposed Activities
The digital patient organoid (DPO) assay is a microfluidic miniature organoid technology that allows high-throughput drug testing.
Area of Impact
Our functional DPO assay will guide personalized therapy in patients with MBC and fulfill a gap of huge unmet need
Mechanism of Action
DPO is a microfluidic miniature organoid technology that enables breast cancer stem cells to form organoids rapidly in the presence of original tumor stromal and immune cells in droplet-sized (250 uM) balls made of extracellular matrix, which is a high-throughput, high-fidelity patient-derived model for rapid drug testing and maintains the original tumor microenvironment and enable personalized treatment for patients with metastatic cancers.
Unmet Medical Need
Metastatic breast cancer (MBC) remains incurable despite recent incorporation of antibody drug conjugates (ADCs). With the fast-paced clinical development of multiple ADCs in the MBC space, lack of trial data or clinical algorithm guiding subsequent therapy following initial ADC resistance, such as a different ADC or combination. There is urgent need for development of novel precision medicine tool using a reliable and rapid turn-round assay guiding treatment selection in these patients.
Project Objective
Pre-IND
Major Proposed Activities
- To assess the DPO platform’s ability to predict patient treatment response to therapy in a prospective clinical study
- To conduct high-throughput screening to identify individualized recommendations of therapy for ADC-mediated drug resistance
- To understand the molecular mechanism of ADC resistance to T-DXd and SG.
Statement of Benefit to California:
Metastatic breast cancer (MBC) remains incurable and 2nd leading cause of cancer death in women in California. The precision medicine treatment for MBC is hindered by lack of functional tools predicting drug sensitivity. Our tool enables high throughput drug testing for faster and more effective identification of therapeutic agents or combination for treatment of MBC, an enormous benefit for the healthcare of Californians.